Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Talphera Inc News

    1,03 $ -8,04% -0,09 $
    In : 0,9635 € | 16:18:01 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3DWPN
    ISIN: US00444T2096
    US-Symbol: TLPH
    Typ: Aktie

    Talphera Inc News

    06.03.24 - PR Newswire
    Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
    Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update PR Newswire
    01.03.24 - PR Newswire
    Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
    Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members PR Newswire
    26.02.24 - PR Newswire
    Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024
    Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024 PR Newswire
    18.01.24 - PR Newswire
    Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
    Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-​Dilutive Royalty Monetization and Equity Offering PR Newswire
    09.01.24 - PR Newswire
    AcelRx Announces Rebranding With Name Change to Talphera, Inc.
    AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire
    12.12.23 - PR Newswire
    AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
    AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire
    08.11.23 - PR Newswire
    AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire
    07.11.23 - PR Newswire
    AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study
    AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study PR Newswire
    26.10.23 - PR Newswire
    AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
    AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 PR Newswire
    03.10.23 - PR Newswire
    AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
    AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study PR Newswire
    06.09.23 - PR Newswire
    AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
    AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference PR Newswire
    10.08.23 - PR Newswire
    AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
    AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire
    27.07.23 - PR Newswire
    AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023
    AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023 PR Newswire
    21.07.23 - PR Newswire
    AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules
    AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-​The-Market Under Nasdaq Rules PR Newswire
    18.07.23 - PR Newswire
    AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
    AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-​The-Market Under Nasdaq Rules PR Newswire
    10.05.23 - PR Newswire
    AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
    AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire
    27.04.23 - PR Newswire
    AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023
    AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023 PR Newswire
    05.04.23 - PR Newswire
    AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
    AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals PR Newswire
    30.03.23 - PR Newswire
    AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
    AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
    21.03.23 - PR Newswire
    AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
    AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 PR Newswire

    Newssuche

    Videos

    newspaper
    08:40 Uhr +7,82%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »